Quick Facts

• Primary Therapeutic Domain: Supports the management of iron deficiency anemia.
• Use Case: Recommended for individuals who have demonstrated intolerance to or an inadequate response following prior oral iron therapy.

---

Iron Dextran is an iron replacement product used to address documented iron deficiency anemia in adult and pediatric patients. Iron is an essential mineral required by the body to support the formation of red blood cells, which are crucial for oxygen transport.

This injectable formulation is typically reserved for individuals who have established iron deficiency and cannot achieve a satisfactory outcome with oral iron supplementation, or who cannot tolerate the oral form. The medication is used to replenish total body iron stores, which supports the body's capacity to restore hemoglobin levels.

The therapeutic application of Iron Dextran is part of an overall strategy to manage the underlying iron deficient state. Clinical investigations have supported its role in patients with various causes of iron deficiency where oral iron is deemed inappropriate or ineffective.

Iron Dextran is reserved for individuals with documented iron deficiency who cannot tolerate oral iron supplementation or have had an unsatisfactory response to it. Official regulatory documents define clear populations for eligibility, caution, and absolute prohibition.

Contraindicated Populations (Must Not Use)

This medicine is strictly prohibited for patients with:

• A known hypersensitivity to iron dextran or any ingredient in the formulation.
• Any form of anemia not associated with iron deficiency.
• Evidence of iron overload, such as hemochromatosis or hemosiderosis.
• Acute phase of infectious kidney disease or those with an acute or chronic infection.

Eligibility by Age and Physiological State

Population	Regulatory Status
Adults	Eligible for the labeled indication.
Pediatric Patients	Approved for use in patients aged 4 months and older.
Infants	Not recommended for use in infants under 4 months of age.
Pregnancy	Category C (US FDA). Use is conditional: benefit must justify the potential risk to the fetus.
Lactation	Caution should be exercised when administered to a nursing woman.

Restricted or Conditional Use

Official labeling requires special caution and monitoring in individuals with:

• Serious impairment of liver function (monitor for iron toxicity).
• Pre-existing cardiovascular disease (adverse reactions may exacerbate complications).
• A history of significant allergies and/or asthma or multiple drug allergies (increased risk of hypersensitivity reactions).
• Rheumatoid arthritis (risk of acute exacerbation of joint pain and swelling).

Interactions with other medicines and products

The interaction profile of Iron Dextran is governed by its injectable administration route, its potential for pharmacodynamic risk enhancement, and its interference with specific diagnostic assays. All interaction information is based strictly on government regulatory labeling.

---

Drug–Drug and Administration Timing Interactions

Interacting Product Category	Official Interaction Outcome	Administration Restriction
Oral Iron Preparations	Reduces the absorption of the oral product.	Oral iron therapy should not be started until at least five days following the last injection.
ACE Inhibitors (e.g., Captopril, Enalapril)	May increase the risk for anaphylactic-type reactions.	Co-administration requires caution regarding increased risk.

---

Drug/Laboratory Test Interactions

Iron Dextran interacts with the reagents and procedures used for various diagnostic tests, which can result in misleading values:

• Serum Iron Determinations may be rendered meaningless for up to three weeks following the administration of the medicine.
• The product may cause falsely elevated values of serum bilirubin and falsely decreased values of serum calcium.
• Bone scans utilizing technetium-labeled agents have been reported to show reduced bony uptake following administration.

Other Restrictions

This medicine must not be mixed with other medicinal products in the same solution; only 0.9% sodium chloride or 5% glucose solution may be used for dilution.

How Iron Dextran Bayer Works

The mechanism of Iron Dextran is centered on utilizing the body's natural systems for the controlled delivery of elemental iron. This action relies on two primary biological domains: specialized cellular processing and systemic transport for the iron substrate.

Macrophage-Mediated Controlled Release

Following administration, the Iron Dextran colloidal suspension relies on the Reticuloendothelial System (RES) for activation. Specialized phagocytic cells, primarily macrophages, capture and internalize the complex. Within the macrophage's lysosomes, the stabilizing dextran shell is enzymatically degraded, facilitating the slow and controlled release of the elemental ferric iron ( Fe^3+) core. This managed breakdown regulates the rate of iron entry into the plasma.

Transferrin Transport and Heme Synthesis Support

The released iron immediately binds to the transport protein Transferrin for delivery through the plasma. Transferrin-bound iron is subsequently internalized by Transferrin Receptors on developing red blood cells in the bone marrow. This targeted delivery provides the essential substrate directly to the Heme synthesis pathway, thereby supporting and accelerating Erythropoiesis. This resulting molecular cascade leads to the increased synthesis of Hemoglobin and the restoration of Ferritin (storage iron), which contributes to oxygen-carrying capacity.

Official Administration Guidelines

Iron Dextran is administered as a parenteral injectable solution (50 mg elemental iron/mL), with the dose and schedule strictly determined by the patient’s iron deficit. Oral iron preparations must be discontinued before starting treatment with this medicine.

---

Administration Scope and Routes

Feature	Official Instruction
Route of Administration	Intravenous (IV) injection or deep Intramuscular (IM) injection (using the Z-track technique).
Preparation	Do not mix with other medications. The IV form is administered undiluted at a slow rate, not to exceed 50 mg (1 mL) per minute.
Setting	Must be administered in a setting where resuscitation equipment and trained personnel are immediately available.

---

Dosage and Treatment Schedule

Dosage is not a fixed amount but is determined by a calculation based on the patient's Lean Body Weight (LBW) and the difference between their Desired Hemoglobin (Hb) and Observed Hemoglobin (Hb).

• Maximum Daily Dose: The maximum daily dose for most adult and pediatric patients (over 10 kg) is 2 mL (100 mg elemental iron). Infants under 5 kg have a maximum daily dose of 0.5 mL (25 mg).
• Frequency: Doses are typically administered once daily (qDay).
• Duration: Administration continues until the calculated total required dose for iron deficit correction and store replenishment has been fully delivered.

Pre-Treatment Protocol

Prior to the first therapeutic dose, a mandatory initial test dose of 0.5 mL (25 mg iron) must be administered. The full therapeutic dose should not be given until the patient has been observed for at least one hour following the test dose.

This calculated, parenteral administration sequence ensures the precise delivery of the total required iron amount, adhering strictly to official procedural steps.

Iron Dextran Bayer: Recent Clinical Evidence

Overview of Clinical Evaluation for Iron Deficiency Anemia

This section will summarize the types of clinical studies, including randomized trials and observational analyses, that have examined Iron Dextran as an iron replacement therapy for patients unable to tolerate or respond adequately to oral iron supplements.

Research has evaluated Iron Dextran in the context of documented Iron Deficiency Anemia (IDA). Evidence comes from various types of research, including comparisons against oral iron, other intravenous iron products, and studies tracking patients over defined periods. The studies focused on populations with challenges such as malabsorption or chronic blood loss. In these studies, findings described patterns observed in monitored patients, and research explored how iron levels evolved in the observed populations.

---

Outcomes Measured in Clinical Research

This part outlines the high-level endpoints used by researchers. Studies monitored changes in key blood components, specifically Hemoglobin (Hb) concentration and iron storage biomarkers like serum ferritin and Transferrin Saturation (TSAT). Studies report measurements of these markers over defined time intervals in the observed groups, as evaluated by researchers. Findings describe patterns related to measurements of target Hemoglobin levels and iron storage reserves.

---

Research in Specific Patient Groups

Iron Dextran was evaluated in patient groups including adults with Chronic Kidney Disease (CKD) and patients with other conditions marked by functional limitations or gastrointestinal disorders leading to malabsorption. Findings apply only to the populations studied and suggest patterns related to changes in their iron status. Pediatric patients (children aged 4 months and older) and pregnant women were also studied, examining measurements of maternal and neonatal iron status.

---

Follow-up and Durability Data

The majority of studies monitored treatment responses over short-term to intermediate time intervals. Evaluation of primary outcomes commonly took place around 4 to 8 weeks (one to two months) after the treatment was given. Research highlights changes measured during this study period. However, follow-up durations were limited in many of the key trials, meaning there is limited information for long-term outcomes and the sustained maintenance of iron stores over many years.

---

Research Gaps and Uncertainties

Research related to the core indication is available; however, certain aspects remain uncertain. Long-term effects are not fully established. Furthermore, comparative evidence is lacking when assessing Iron Dextran head-to-head against all newer intravenous iron products. While data exists, for certain highly specific subgroups, findings were mixed or the sample sizes were modest, meaning data for certain groups remain insufficient.

Common questions about Iron Dextran Bayer (FAQ)

Q: Is Iron Dextran Bayer the same as other iron infusions, and what's the difference?

Iron Dextran is classified as a parenteral iron replacement product. According to official product information, it is a specific complex of Ferric Hydroxide (the iron core) coated with a type of sugar called low-molecular-weight Dextran. This specific chemical structure is a key feature, as other injectable iron replacement products utilize different carbohydrate carriers.

Q: Have studies shown Iron Dextran Bayer to be effective for chronic anemia?

Clinical trials and official efficacy data have examined the use of Iron Dextran in specific patient groups, such as those with Chronic Kidney Disease. Findings from these studies described patterns of increased Hemoglobin, Ferritin, and Transferrin Saturation levels, which supported the medicine's use for documented iron deficiency anemia in the populations studied.

Q: Can people with kidney problems use Iron Dextran Bayer?

Regulatory information indicates that the medicine has been evaluated in patients with Chronic Kidney Disease (CKD). However, it is strictly contraindicated (must not be used) in patients experiencing the acute phase of an infectious kidney disease.

Q: Is Iron Dextran Bayer used long-term or is it only for short-term use?

The medicine is administered until the precise, calculated total required dose needed to correct the iron deficit is fully delivered. Regulatory documents note that the risk of iron overload (Hemosiderosis) is associated with repeated administration or high total doses.

Q: How does the dextran part of the medicine function?

The Dextran component acts as a protective coating to stabilize the iron core. Official pharmacology descriptions state that after the injection, specialized cells called macrophages slowly break down this Dextran shell, which allows for the slow and controlled release of the iron into the system.

Q: What kind of side effects are common after getting an Iron Dextran Bayer infusion?

Official documentation lists several common reactions. These include systemic effects such as nausea, vomiting, dizziness, hypotension (low blood pressure), and chest pain. Reactions at the injection site, like pain and a brown pigmentation, are also frequently noted.

Q: Can Iron Dextran Bayer cause a skin reaction or change in color?

Yes, official adverse reaction reports list several skin-related reactions. These include a potential rash or hives, flushing (feeling warm or red), and brown pigmentation at the injection site. This pigmentation is due to the iron and is noted in official documentation as an injection site reaction.

Q: Is it possible for Iron Dextran Bayer to interfere with thyroid medication?

Regulatory documents for iron dextran injection do not list a specific direct interaction with common thyroid medications. Other oral iron products are generally known to potentially interfere with the absorption of Levothyroxine.

Q: Can I drive right after receiving Iron Dextran Bayer?

Official documents list dizziness and hypotension (low blood pressure) as potential common side effects that may affect the ability to operate machinery.

Q: Is a fever after the Iron Dextran Bayer infusion a normal expectation?

According to regulatory documents, fever is listed as a potential reaction. It is often part of a delayed reaction pattern that may manifest 24 to 48 hours after the infusion, and typically resolves on its own within a few days.

Q: Can Iron Dextran Bayer make pre-existing joint pain worse?

Official warnings describe a need for special monitoring in patients with Rheumatoid Arthritis due to a risk of the acute exacerbation of joint pain and swelling. Arthralgia (joint pain) is also listed as a potential delayed side effect that can occur after the infusion.

Q: Are there different brand names for the same Iron Dextran compound?

Yes, authoritative medical and regulatory sources note that the Iron Dextran compound is marketed and distributed under various brand names in different regions, such as INFeD and Dexferrum in the United States.

Q: What should be monitored after a person receives Iron Dextran Bayer?

Regulatory documents require that patients be observed for at least one hour after a test dose to monitor for any signs of an acute hypersensitivity reaction. Furthermore, clinical studies and practice guidelines focus on monitoring key markers like Hemoglobin, Ferritin, and Transferrin Saturation at defined intervals.

Q: Can Iron Dextran Bayer cause temporary changes in taste or smell?

Yes, official reports of adverse reactions have noted that some patients may experience Dysgeusia (a change in taste) and a Metallic Taste as potential side effects associated with the medicine.

Q: Are there any specific foods or drinks to avoid while receiving Iron Dextran Bayer?

Official regulatory documents and interaction profiles do not list specific foods or drinks that must be avoided while receiving the injectable medicine. Interaction warnings focus primarily on other medications and products, such as Oral Iron Preparations.

Q: Is it common to feel flushed or warm during the infusion?

Flushing—a feeling of warmth, redness, or tingling—is listed in official adverse event reports as a potential side effect. This is generally noted as a rapid reaction that may occur during the administration of the infusion.

Q: Does Iron Dextran Bayer cause long-term discoloration of the skin or veins?

Brown pigmentation at the injection site is a known potential reaction. If the medicine leaks into the surrounding tissue (extravasation), official reports note this resulting skin staining may be long-lasting or potentially permanent.

Q: What are the known potential benefits of Iron Dextran Bayer based on official research?

The purpose of the medicine, as described in official research and labeling, is to deliver iron to the body. This supports the synthesis of the oxygen-carrying component Hemoglobin and helps restore long-term iron storage reserves known as Ferritin, thereby addressing documented iron deficiency anemia.

Q: What does the research say about Iron Dextran Bayer use in children?

The medicine is approved for use in pediatric patients aged 4 months and older who have documented iron deficiency and cannot tolerate or respond to oral iron. Studies have evaluated the change in iron status measurements in these observed pediatric groups.

Storage and Disposal: Official Regulatory Information

The official labeling for Iron Dextran Injection specifies mandatory conditions for maintaining product integrity.

Scope Item	Official Requirement (Based on Regulatory Labeling)
Labeled storage temperature requirements:	Store at controlled room temperature (15 to 30 C or 59 to 86 F).
Stability after opening (if applicable):	Once a multiple-dose vial is first entered, use the remaining solution within 90 days (or 3 months).
Handling requirements:	Must be protected from freezing.
Child-protection storage requirements:	Keep out of reach of children.
Disposal instructions:	Dispose of unused product or waste material in accordance with local regulations for pharmaceutical waste.

Official regulatory documents require the product to be stored at a specific controlled room temperature and explicitly state that it must be protected from freezing. For multi-dose containers, a 90-day stability limit is enforced after the vial is first punctured. The label also mandates that the medicine be stored out of reach of children and that disposal must adhere to local regulatory guidelines.